secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0001104659-22-127969
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 1.01, 2.03, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MedTech shareholders approve deadline extension; 96% of public shares redeemed, leaving ~$19.7M in trust
--------------------------------------------------------------------------------

- Stockholders approved extension of business combination deadline from Dec 22, 2022 to June 22, 2023.
- 23,046,578 Public Shares (96%) redeemed for ~$232.37M; only ~$19.70M remains in trust after redemptions.
- Sponsor issued up to $468,821 Extension Note and up to $1,000,000 Working Capital Note for extension and working capital.
- Directors Karim Karti, Martin Roche, Thierry Thaure, Manuel Aguero re-elected as Class I directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465922127969/0001104659-22-127969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465922127969/tm2232875d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-127969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer